Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtre
2.
Rev. méd. Chile ; 136(3): 359-366, mar. 2008. ilus, graf
Article Dans Espagnol | LILACS | ID: lil-484908

Résumé

Acute right ventricular failure after cardiac surgery occurring in the first postoperative hours is associated with a bad prognosis. We have used a centrifugal pump either for ¡eft, right or biventricular assistance. However, the use of this device for pure right ventricular assistance is rare. We report a 30 year-old female undergoing a mitral valve replacement and a 42 year-old male undergoing a cardiac transplantation, who had a successful right ventricular assistance using a centrifugal pump, due to a failing right ventricle, as the result of insufficient myocardial protection and severe pulmonary hypertension. These two cases illustrate the value of the mechanical ventricular assist device for the treatment of right heart failure.


Sujets)
Adulte , Femelle , Humains , Mâle , Dispositifs d'assistance circulatoire , Dysfonction ventriculaire droite/thérapie , Maladie aigüe , Épinéphrine/usage thérapeutique , Défaillance cardiaque/thérapie , Hypertension pulmonaire/thérapie , Norépinéphrine/usage thérapeutique , Facteurs temps , Résistance vasculaire/effets des médicaments et des substances chimiques , Vasoconstricteurs/usage thérapeutique
3.
Rev. méd. Chile ; 134(10): 1249-1257, oct. 2006. ilus, tab
Article Dans Espagnol | LILACS | ID: lil-439915

Résumé

Background: The optimal dose of Streptokinase in the treatment of acute myocardial infarction is not well established. Apparently, the thrombolytic efficacy would not increase with doses over 750.000 units. Aim: To compare the effectiveness and safety of treatment with low doses of Streptokinase, ranging from 500.000 to 750.000 units, in patients with ST elevation acute myocardial infarction. Patients and methods: From September 1993 to September 1998, the GEMI register of patients with acute myocardial infarction, was carried out in 37 hospitals, incorporating 4,938 patients. Of these, 1,631 patients received streptokinase. According to the administered dose of Streptokinase, patients were divided in two groups: 1,465 patients who received 1.5 millions U in 60 minutes (classical therapy group), and 166 patients with ischemic chest discomfort and either ST-segment elevation or left bundle-branch block on the electrocardiogram, who received 500.000 to 750.000 U streptokinase administered in no more than 30 minutes, with heparin, within 0 to 6 hours of symptom onset. Successful reperfusion, mortality, complications, and hospital outcome was evaluated in both groups. Results: The low dose group of patients had a better reperfusion criteria profile. No differences between groups were observed in patient evolution, mortality, maximum Killip classification, post myocardial infarction heart failure, ischemic complications, arrhythmias or mechanical complications. Conclusions: These results suggest that streptokinase in low doses is at least as effective as classical therapy, in the treatment of ST elevation acute myocardial infarction.


Sujets)
Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Fibrinolytiques/administration et posologie , Infarctus du myocarde/traitement médicamenteux , Streptokinase/administration et posologie , Traitement thrombolytique , Loi du khi-deux , Creatine kinase/sang , Électrocardiographie , Fibrinolytiques/effets indésirables , Héparine/administration et posologie , Héparine/effets indésirables , Infarctus du myocarde/complications , Reperfusion myocardique , Mesure de la douleur , Études prospectives , Facteurs de risque , Streptokinase/effets indésirables , Traitement thrombolytique/effets indésirables , Résultat thérapeutique
4.
Bol. Hosp. Viña del Mar ; 58(4): 160-163, dic. 2002. tab
Article Dans Espagnol | LILACS | ID: lil-410275

Résumé

Se presenta la experiencia en transplante cardíaco del Hospital Dr. Gustavo Fricke de Viña del Mar desde la creación del Comité de Enfermedades Cardiorespiratorias Terminales en 1998. Actualmente hay 9 pacientes en control. Se analizan los resultados a corto y largo plazo, la terapia utilizada y las complicaciones más frecuentes y su manejo


Sujets)
Humains , Mâle , Adolescent , Femelle , Adulte d'âge moyen , Immunosuppresseurs/usage thérapeutique , Cardiopathies , Immunosuppression thérapeutique , Défaillance cardiaque/anatomopathologie , Cardiomyopathie dilatée/étiologie , Cardiomyopathie restrictive/étiologie , Transplantation cardiaque , Anti-infectieux/usage thérapeutique , Chili , Ventilation artificielle
SÉLECTION CITATIONS
Détails de la recherche